Parth Mehrotra Sells 26,763 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CEO Parth Mehrotra sold 26,763 shares of Privia Health Group stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $21.90, for a total transaction of $586,109.70. Following the completion of the transaction, the chief executive officer owned 609,181 shares of the company’s stock, valued at $13,341,063.90. This trade represents a 4.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Parth Mehrotra also recently made the following trade(s):

• On Friday, March 13th, Parth Mehrotra sold 27,229 shares of Privia Health Group stock. The stock was sold at an average price of $21.52, for a total transaction of $585,968.08.
• On Tuesday, March 10th, Parth Mehrotra sold 21,097 shares of Privia Health Group stock. The shares were sold at an average price of $22.71, for a total transaction of $479,112.87.
• On Monday, March 9th, Parth Mehrotra sold 41,999 shares of Privia Health Group stock. The stock was sold at an average price of $22.86, for a total transaction of $960,097.14.
• On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The stock was sold at an average price of $23.15, for a total value of $496,336.00.

Privia Health Group Trading Up 0.6%

Shares of NASDAQ PRVA opened at $22.10 on Wednesday. The stock has a market cap of $2.73 billion, a P/E ratio of 130.00, a PEG ratio of 1.38 and a beta of 0.82. The business’s fifty day simple moving average is $22.80 and its 200-day simple moving average is $23.61. Privia Health Group, Inc. has a 12-month low of $18.77 and a 12-month high of $26.51.

Privia Health Group (NASDAQ:PRVA) last released its earnings results on Thursday, February 26th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The firm had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same period in the previous year, the firm posted $0.21 EPS. Privia Health Group’s revenue for the quarter was up 17.4% on a year-over-year basis. On average, equities analysts forecast that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PRVA has been the subject of a number of analyst reports. Citigroup lowered their price objective on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Stephens reaffirmed an “overweight” rating and issued a $32.00 target price on shares of Privia Health Group in a report on Thursday, December 4th. Truist Financial lifted their price target on shares of Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Canaccord Genuity Group boosted their price target on shares of Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, Wolfe Research set a $31.00 price objective on shares of Privia Health Group in a research report on Tuesday, January 6th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Institutional Trading of Privia Health Group

A number of hedge funds have recently bought and sold shares of the company. Van Berkom & Associates Inc. raised its holdings in Privia Health Group by 30.1% in the 3rd quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock valued at $93,987,000 after acquiring an additional 873,344 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Privia Health Group by 5.3% during the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after purchasing an additional 607,447 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its holdings in shares of Privia Health Group by 139.4% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock worth $19,946,000 after purchasing an additional 489,866 shares during the last quarter. Algert Global LLC grew its position in shares of Privia Health Group by 277.4% in the third quarter. Algert Global LLC now owns 484,304 shares of the company’s stock valued at $12,059,000 after purchasing an additional 355,966 shares during the period. Finally, Freestone Grove Partners LP grew its position in shares of Privia Health Group by 40.6% in the fourth quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock valued at $28,768,000 after purchasing an additional 350,194 shares during the period. Institutional investors and hedge funds own 94.48% of the company’s stock.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.